Sharareh Seifi, Babak Salimi, Zahra Esfahani Monfared, Cyrus Sabahi, Hamidreza Kafi, & Adnan Khosravi. (2023). Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: A post-marketing surveillance. Taylor & Francis Group.
Lua i Stíl Chicago (17ú heag.)Sharareh Seifi, Babak Salimi, Zahra Esfahani Monfared, Cyrus Sabahi, Hamidreza Kafi, agus Adnan Khosravi. Alvopem® (pemetrexed) Safety Assessment in Patients with Non-small Cell Lung Cancer or Malignant Pleural Mesothelioma: A Post-marketing Surveillance. Taylor & Francis Group, 2023.
Lua MLA (9ú heag.)Sharareh Seifi, et al. Alvopem® (pemetrexed) Safety Assessment in Patients with Non-small Cell Lung Cancer or Malignant Pleural Mesothelioma: A Post-marketing Surveillance. Taylor & Francis Group, 2023.